Background: Effects of oral anticoagulation in chronic kidney disease (CKD) are uncertain.
C
hronic kidney disease (CKD) is a prothrombotic state that is associated with substantially increased risks for arterial and venous thromboembolism (VTE) (1) . In addition, atrial fibrillation (AF) is highly prevalent in this population, affecting 18% of patients with CKD (2) and 12% to 25% of those with dialysis-dependent end-stage kidney disease (ESKD) (3, 4) . The presence of CKD increases risks for stroke or systemic embolism, congestive heart failure, myocardial infarction, and allcause death among patients with AF (5, 6) . Compared with persons with normal kidney function, risk for VTE is almost 2-fold greater among those with an estimated glomerular filtration rate (eGFR) between 15 and 59 mL/min/1.73 m 2 (7) and 3-fold greater in those with dialysis-dependent ESKD (8) . Venous thromboembolism in ESKD is also associated with increased risks for bleeding and all-cause death (8) . Other common clinical manifestations of increased thrombotic risk in CKD include acute coronary syndrome, stroke, peripheral artery occlusion, and dialysis access thrombosis (1, 9) .
Anticoagulant therapy is an important intervention in the prevention of cardiovascular thrombotic and VTE events. Evidence-based treatment guidelines recommend anticoagulation for prevention of stroke in patients with nonvalvular AF and a CHA 2 DS 2 -VASc score of 2 or greater in men or 3 or greater in women (10, 11) , for VTE in patients who have had major orthopedic or nonorthopedic surgery or hospitalized patients with acute illness (12) , and for recurrent VTE in patients with VTE disease (13) .
Patients with advanced CKD and ESKD who have AF are prescribed oral anticoagulant (OAC) therapy less frequently than those with normal kidney function (3, 14) . Use of warfarin in patients receiving dialysis who have AF varies from 2% in Germany to 37% in Canada (3) . The low rates of anticoagulant therapy use in advanced CKD and ESKD may be due to the increased risk for bleeding, uncertainty about potential benefits in this population, warfarin-associated calciphylaxis, and warfarin-related nephropathy (15, 16) . In CKD, risk for major bleeding increases linearly with decreasing eGFR (17) . In patients with dialysis-dependent ESKD, bleeding risk is further increased with incremental use of antithrombotic agents, such as warfarin and antiplatelets (18) . The exclusion of patients with CKD from nearly 90% of trials evaluating anticoagulants has contributed to uncertainty about the role of anticoagulant therapy in CKD (19) . The aim of the current systematic review was to evaluate the benefits and harms of OAC therapy for a range of clinical indications in patients with CKD stages 3 to 5, including those receiving dialysis.
METHODS
This systematic review and meta-analysis was conducted according to the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) statement (20) . The protocol for this review was prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO) on 4 December 2017 (www .crd.york.ac.uk/prospero/display_record.php?RecordID =79709).
Data Sources and Searches
Relevant studies were identified by performing English-language searches of MEDLINE (inception to February 2019), EMBASE (inception to February 2019), and the Cochrane Central Register of Controlled Trials (January 2019) using the search strategy described in Supplement Table 1 (available at Annals.org). In addition, reference lists of relevant systematic reviews were searched. ClinicalTrials.gov was searched (25 February 2019) using the following terms: chronic kidney disease, renal dialysis, atrial fibrillation, and anticoagulation.
Study Selection and Outcomes
Studies were eligible for inclusion if they were randomized controlled trials; included adults with CKD (creatinine clearance [CrCl] <60 mL/min or eGFR <60 mL/min/1.73 m 2 ) or dialysis-dependent ESKD; compared a vitamin K antagonist (VKA) or non-vitamin K oral anticoagulant (NOAC) with another OAC, placebo, low-molecular-weight heparin (LMWH), aspirin, or no study medication; and reported efficacy, bleeding outcomes, or both. All indications for anticoagulation were eligible for inclusion. Two authors (J.T.H. and B.L.N.) independently reviewed each title and abstract and reviewed the full texts of shortlisted studies. Disagreements about study eligibility were resolved via consultation with 2 other authors (V.P. and S.V.B.). If multiple secondary publications of the same trial were identified, the one with the most complete data was used and additional data from secondary sources were extracted. Incomplete or unpublished trial data were requested from the investigators. The outcomes of this systematic review were stroke or systemic embolism in AF, nonhemorrhagic stroke, hemorrhagic stroke, allcause or cardiovascular death, VTE or VTE-related death, myocardial infarction, composite cardiovascular events (cardiovascular or all-cause death, nonfatal myocardial infarction, or stroke), dialysis access thrombotic events, major bleeding, major or nonmajor clinically relevant bleeding, and intracranial hemorrhage.
Data Extraction and Quality Assessment
Data were extracted independently by 2 authors (J.T.H. and B.L.N.), and disagreements were resolved via consultation with 2 other authors (V.P. and S.V.B.). A standardized form was used to extract the following data: patient demographic characteristics, study design and conduct, indication for anticoagulation, drug dose, nonrandomized co-interventions, follow-up duration, and outcome and bleeding events. The methodological quality of each included study was assessed at the outcome level independently by 2 authors (J.T.H. and B.L.N.) using the risk-of-bias assessment tool developed by the Cochrane Bias Methods Group (21) .
Data Synthesis and Analysis
The results were expressed as risk ratios (RRs) with 95% CIs. A treatment group continuity correction was used if there were 0 events in 1 group in a trial. For trials with 3 groups comparing 2 different doses of NOACs with VKAs, data from only the high-dose NOAC groups were used for the main analyses to avoid potentially uninterpretable results caused by merging of the benefits and harms of different doses; this was similar to the method used in a previous meta-analysis (22) . Additional analyses were conducted by combining data from both high-and low-dose groups of NOACs. Summary estimates were obtained with a randomeffects model using the Paule-Mandel method (23) . If data on the number of events and participants were not reported, a generic inverse variance meta-analysis was performed by calculating the log of the hazard ratio and its SE from the reported hazard ratio and its CI. Statistical heterogeneity across studies was estimated using the I 2 test, with values of 25%, 50%, and 75% corresponding to low, moderate, and high heterogeneity, respectively (24) . Statistical analyses were performed using Stata/MP, version 15.1 (StataCorp), and R, version 3.5.3 (R Foundation for Statistical Computing).
Using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach, 3 authors (J.T.H., B.L.N., and L.P.C.) summarized the certainty of the evidence based on the following domains: within-study risk of bias, indirectness of evidence, unexplained heterogeneity or inconsistency of results, and imprecision of results. Disagreements were resolved via consultation with 2 other authors (M.J. and S.V.B.) (25) . Because all meta-analyses involved fewer than 10 trials, small-study effects (publication bias) were not assessed and publication bias was not included in ratings of certainty of evidence (26) .
Role of the Funding Source
This study received no funding. Table 2 (available at Annals.org).
RESULTS

Selection and Description of Studies
Non-vitamin K oral anticoagulants were compared with VKAs (15 trials, 16 495 participants), placebo (10 trials, 11 683 participants), LMWH (5 trials, 1720 participants), and aspirin (4 trials, 2690 participants). Vitamin K antagonists were compared with placebo (4 trials, 408 participants), no study medication (4 trials, 277 participants), LMWH (2 trials, 293 participants), and aspirin (1 trial, 516 participants). The interventional agents were rivaroxaban (13 trials), dabigatran (8 trials), apixaban (7 trials), edoxaban (5 trials), betrixaban (1 trial), fixed-dose (1 or 2 mg) or low-intensity (target international normalized ratio, 1.4 to 1.9) warfarin (6 trials), and adjusted-dose (target international normalized ratio, 1.5 to 2.5 or 2 to 3) warfarin or acenocoumarol (5 trials). The funding source was not reported in 4 trials. Thirtynine of the remaining 41 (95%) trials were sponsored by pharmaceutical companies.
Risk of Bias
Risk-of-bias assessment at the outcome level is summarized in Supplement Table 3 (available at Annals .org). Random sequence generation and allocation concealment were reported using low-risk methods in 80% of trials reporting stroke or systemic embolism and major bleeding in participants with AF. Random sequence generation and allocation concealment were reported using low-risk methods in all trials reporting VTE or VTE-related death in participants with acute VTE or those requiring thromboprophylaxis, and major adverse cardiovascular events in participants with cardiovascular disease other than AF. Trials that involved participants with dialysis-dependent ESKD and reported hemodialysis access thrombosis or malfunction, allcause death, and major bleeding generally had high or unclear risk of bias in the domains of random sequence generation and allocation concealment.
Effects of Interventions
Atrial Fibrillation
None of the 11 trials involving participants with AF included those with dialysis-dependent ESKD. Anticoagulation was used for prevention of stroke or systemic embolism in 7 trials, acute coronary syndrome or percutaneous coronary intervention in 2 trials, and periprocedural anticoagulation in participants undergoing cardioversion or catheter ablation in 1 trial each. No trial compared an OAC with no anticoagulation in patients Figures 1 and 5) . Figure 9 , available at Annals.org).
Anticoagulation Required for Thromboprophylaxis
We found no clear differences between NOACs and LMWH in risks for VTE or VTE-related death ( 
DISCUSSION
This review provides a comprehensive overview of available data describing the effects of anticoagulation for patients with CKD and a range of comorbidities or other risk factors. It identifies clear findings that can be used to guide treatment but also several areas where data are inadequate and further studies are urgently required. A key finding was that in patients with AF and early-stage CKD, NOACs were superior to VKAs, with relative risk reductions of 21% for stroke or systemic embolism, 52% for hemorrhagic stroke, and 51% for intracranial hemorrhage. However, NOACs did not reduce risk for nonhemorrhagic stroke in patients with AF, and although they reduced risk for major bleeding, this finding was not statistically significant. Compared with placebo, NOACs reduced risk for recurrent VTE or VTE-related death in patients with CKD receiving acute VTE treatment; however, compared with VKAs, this effect was uncertain. These data suggest that NOACs may be a reasonable treatment option for patients with CKD who develop VTE, but further data would be helpful. In all trials combined, compared with VKAs, highdose NOACs reduced risk for major bleeding, although this result was not statistically significant. In contrast, for patients with advanced CKD (CrCl <25 mL/min), including dialysis-dependent ESKD, no data were available on the effects of VKAs or NOACs on prevention of stroke or systemic embolism in patients with AF or on VTE and VTE-related death. 
GRADE
Certainty of Evidence
Favors intervention Favors control
ASA = aspirin; GRADE = Grading of Recommendations Assessment, Development and Evaluation; LMWH = low-molecular-weight heparin; NA = not applicable; NOAC = non-vitamin K oral anticoagulant; RR = risk ratio; VKA = vitamin K antagonist. * The number of events was not reported in 1 trial; hence, generic inverse variance meta-analysis was performed.
Although rates of ischemic and hemorrhagic stroke and intracranial hemorrhage were not reported in all trials involving participants with AF, the benefit of reduced stroke or systemic embolism with NOACs may have been driven mainly by a reduction in hemorrhagic stroke. A similar finding was reported in a previous systematic review of 4 randomized trials comparing NOACs with VKAs (22). The excess burden of AF, cardiovascular thrombotic events, and VTE in patients with advanced CKD contributes to their poor survival (5, 6, 8) . Given the greater rates of arterial thromboembolism and VTE in patients with advanced CKD than in patients with normal kidney function, the absolute risk reduction with anticoagulation in this population may be greater. However, this systematic review highlights the absence of evidence in patients with advanced CKD and ESKD, specifically for prevention of stroke or systemic embolism in AF and for recurrent VTE or VTE-related death. The potential benefit of anticoagulation needs to be weighed against the risk for bleeding in this population. The rates of major bleeding with apixaban and warfarin in patients with hemodialysis-dependent ESKD (19.7 and 22.9 per 100 person-years, respectively) (27) are substantially greater than in those with normal or mildly decreased kidney function (2.13 and 3.09 per 100 person-years, respectively) (28) . Furthermore, 60% to 75% of patients with ESKD discontinue OAC therapy within 1 year, possibly because of bleeding (27, 29) . Despite the absence of specific evidence, current guidelines suggest warfarin with a target international normalized ratio of 2.0 to 3.0 or apixaban (class IIa recommendation, moderate-quality evidence) (11) and a time in the therapeutic range greater than 65% to 70% (ungraded consensus-based statements) (10) in patients with CrCl less than 15 mL/min or those with dialysis-dependent ESKD and a CHA 2 DS 2 -VASc score of 2 or greater in men or 3 or greater in women (11) . The lack of evidence-based guidelines strongly suggests that adequately powered randomized trials are required to address the unmet need in this population.
Because of their favorable benefit-risk profile, NOACs are being evaluated for new cardiovascular indications. In early-stage CKD, although NOACs did not reduce major cardiovascular events after acute coronary syndrome, the combination of low-dose rivaroxaban and aspirin was beneficial for this primary outcome in patients with stable coronary or peripheral artery disease in a single trial (30) . A dose of rivaroxaban far below that required for full anticoagulation may be particularly valuable in patients with advanced CKD and ESKD who also have elevated bleeding risk. However, because patients with eGFR less than 15 mL/min/1.73 m 2 were excluded from this trial, this strategy will need to be tested in randomized trials, specifically in patients with advanced CKD and ESKD.
In contrast to the other recent systematic reviews identified in our MEDLINE search, this review demonstrates the superiority of NOACs over VKAs in reducing risk for stroke or systemic embolism in AF (31, 32) . Furthermore, the broad scope of clinical settings in this review allows a more comprehensive understanding of effects. Other strengths were the inclusion of a large number of participants, the robust evaluation of efficacy and bleeding outcomes, and the use of the GRADE approach to assess the body of evidence. These strengths should be weighed against the review's limitations, which were largely due to the limitations of the underlying literature. These include exclusion of patients with dialysis-dependent ESKD and advanced nondialysis CKD, limited information on demographic characteristics of the CKD subgroup, underreporting of organ-specific bleeding data (especially gastrointestinal bleeding), lack of individual-patient data, and suboptimal methodological quality of trials involving participants with dialysis-dependent ESKD. Data on patients with CKD from trials of NOACs were obtained exclusively from subgroup analyses of large trials. The current review was not designed to assess differences among NOACs.
Two In summary, this systematic review demonstrates that NOACs had a benefit-risk profile superior to that of VKAs in patients with early-stage CKD, with significant reductions in stroke or systemic embolism and hemorrhagic stroke in AF. This review also showed a reduction in overall major bleeding risk that was not statistically significant in all trials combined, suggesting that these patients will derive similar or greater benefit compared with those who do not have CKD. However, evidence is insufficient to recommend widespread use of VKAs or NOACs to improve clinical outcomes in patients with advanced CKD and dialysis-dependent ESKD. Adequately powered randomized trials are required to evaluate the benefits and harms of anticoagulant therapy in this patient population.
